Free Trial

Drug companies in opioid crisis donated $27K to Ohio's Ryan

Tim Ryan
FILE—Rep. Tim Ryan, D-Ohio, running for an open U.S. Senate seat in Ohio, speaks, May 3, 2022, in Columbus, Ohio. Ryan, who has made his opponent's questionable record fighting the opioid epidemic a central theme of his campaign for Ohio's open U.S. Senate seat, has accepted campaign donations over the years from drug distributors blamed for key roles in the crisis, an Associated Press review found. (AP Photo/Jay LaPrete, File)

COLUMBUS, Ohio (AP) — Democratic U.S. Rep. Tim Ryan, who has made his opponent's questionable record fighting the opioid epidemic a central theme of his campaign for Ohio's open U.S. Senate seat, has received campaign donations over the years from drug distributors blamed for key roles in the crisis, an Associated Press review found.

The contributions to Ryan from AmerisourceBergen, McKesson and Dublin, Ohio-based Cardinal Health, the three biggest drug distribution companies in the U.S., came in between 2007 and August of this year.

Earlier this year, the companies finalized a $21 billion settlement with state, local and Native American tribal governments and others over the toll of the opioid crisis. The settlement is the largest over opioid claims and keeps the companies from facing thousands of lawsuits.

The trio's combined giving to Ryan of $27,000 represents a fraction of the $50 million he has collected over the course of his career. Still, contributions from those donors are notable as Ryan hammers the spotty record of the anti-opioid nonprofit started by his Republican opponent, “Hillbilly Elegy” author JD Vance.

Ryan's campaign spokesperson called him “one of Congress' most outspoken fighters against the opioid epidemic.” She noted that Cardinal is a major Ohio employer and the companies' donations represent just one-fifth of 1% of the $17 million Ryan raised this quarter alone.

Vance's nonprofit, Our Ohio Renewal, spent far more than that "for political polling and consultant fees to his top political advisor — when it wasn't promoting a Purdue Pharma-linked doctor with a reputation for downplaying the deadly threat of OxyContin,” spokesperson Izzi Levy said.

Vance's campaign said accepting the donations represented “shameless hypocrisy” by Ryan. It had not yet reported its latest fundraising figures Wednesday.

Ryan and Vance are locked in a tight contest for the coveted open Senate seat being vacated by retiring Republican Sen. Rob Portman. Republicans see the seat as a critical one to hold if they hope to retake the Senate, while a flip to Democrats would be a major victory in the increasingly conservative-leaning state.

The distributor most generous to Ryan was from Cardinal Health Inc., a multinational health care services company headquartered in his home state. The company’s PAC has given him $21,000 since 2007, including $5,000 this August. McKesson Corp. Employees PAC gave Ryan $5,000 in 2012. Amerisource Bergen Corp. PAC gave him $1,000 in 2019. The opioid crisis was ongoing during all those years.

The three companies’ PACs have donated nearly $10.8 million combined to a wide range of candidates across the country since 2007, according to campaign finance figures compiled by the nonpartisan Center for Responsive Politics. About $4.5 million of that went to Democrats, and the other roughly $6.2 million went to Republicans. Vance’s campaign has not received any donations from the PACs.

Ryan's early ads called Vance's Our Ohio Renewal a “sham” that “didn't fund a single addiction program” to fight the crisis, but rather backed efforts that “made it worse.” A second ad featured an August Associated Press article detailing a residency the nonprofit organized for an addiction doctor with links to Purdue Pharma, the manufacturer of OxyContin.

Vance has said that he did not know about the addiction doctor’s ties to Purdue Pharma, but that he “remains proud of her work to treat patients, especially those in an area of Ohio who needed it most.”

Ryan's campaign said the congressman had helped bring funding to health care providers and law enforcement officials working to fight opioids and had worked to expand access to treatment for residents with substance abuse issues.

“Tim Ryan has a proven record of working across the aisle to combat this epidemic,” campaign spokesperson Levy said in a statement.

During the same years that the now-shuttered Our Ohio Renewal was operating in southern Ohio, Ryan was casting votes in Congress on a host of bills aimed at tackling various elements of the opioid crisis — sometimes for, sometimes against.

He voted overwhelmingly in support of such efforts — including co-sponsoring the INTERDICT Act praised by President Donald Trump for allocating $15 million to beef up illegal drug screenings on the southern border.

But Ryan also opposed several measures aimed at addressing opioid enforcement and addiction, the AP review found. Those included funding packages aimed at providing medical care to address the problem and legislation intended to crack down on illegal fentanyl trafficking. Levy said the congressman had policy objections to aspects of those bills.

Ryan also missed a vote in 2020 on legislation extending the Drug Enforcement Administration's temporary order listing fentanyl-related substances as Schedule 1 controlled substances. Levy said he was attending a family funeral on that day.

__

Geoff Mulvihill in Cherry Hill, N.J., contributed to this report.

Should You Invest $1,000 in McKesson Right Now?

Before you consider McKesson, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and McKesson wasn't on the list.

While McKesson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report
Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRankâ„¢Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Cardinal Health (CAH)
4.82 of 5 stars
$164.801.7%1.24%25.71Moderate Buy$157.43
McKesson (MCK)
4.3488 of 5 stars
$719.302.0%0.39%27.85Moderate Buy$696.42
Compare These Stocks  Add These Stocks to My Watchlist 

Featured Articles and Offers

Recent Videos

3 Cheap Growth Stocks Set to Explode This Summer
The Next NVIDIA? Quantum Computing Stocks Set for Explosive Growth
5 Stocks to BUY NOW in July 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines